Printer Friendly

Curcumin for ulcerative colitis.

Fifty patients with mild-to-moderate ulcerative colitis that had failed to respond sufficiently to mesalamine were randomly assigned to receive, in double-blind fashion, 3 g per day of curcumin (in 2 divided doses per day before meals) or placebo for 1 month, while continuing mesalamine. In intent-to-treat analysis, the proportion of patients who achieved clinical remission (defined as a score of 2 or lower on the Simple Clinical Colitis Activity Index [SCCAI]) was significantly higher in the curcumin group than in the placebo group (53.8% vs. 0%; p = 0.01). The proportion of patients who had a clinical response (defined as a reduction of at least 3 points in the SCCAI score) was also significantly higher in the curcumin group than in the placebo group (65.3% vs. 12.5%; p < 0.001). Endoscopic remission was seen in 38% of the patients in the curcumin group and 0% of those in the placebo group (p < 0.05). No significant side effects were seen.

Comment: Curcumin, a compound present in turmeric, has anti-inflammatory activity. In a previous study, administration of curcumin reduced the recurrence rate in patients with ulcerative colitis in remission. The results of the present study indicate that the addition of curcumin to mesalamine therapy was effective for inducing clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis that had failed to respond to mesalamine alone.

Lang A et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015; 13:1444-1449.e1.

by Alan R. Gaby, MD

drgaby@earthlink.net

COPYRIGHT 2015 The Townsend Letter Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Literature Review & Commentary
Author:Gaby, Alan R.
Publication:Townsend Letter
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2015
Words:266
Previous Article:Probiotic for periodontal disease.
Next Article:Sugar-sweetened beverages and fatty liver.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters